Global Neurogenetic Testing Market Strategic Research Report

Scope of the Report

The global Neurogenetic Testing market size is predicted to grow from US$ 794 million in 2025 to US$ 1,683 million in 2032; it is expected to grow at a CAGR of 11.4% from 2026 to 2032.

Neurogenetic testing is a molecular and genomic diagnostic approach used to analyze and interpret genes associated with neurological disorders. This testing helps identify whether an individual carries genetic mutations that may cause neurodegenerative diseases, epilepsy, intellectual disability, autism spectrum disorders, movement disorders, and certain hereditary neuropathies. The value of neurogenetic testing lies not only in early disease screening and clinical diagnosis, but also in guiding physicians to develop personalized treatment plans and assisting families with genetic risk assessment and reproductive planning.

Global neurogenetic testing players include Quest Diagnostics, Mayo Clinic, GeneDx, Illumina and Labcorp, etc. Global top five manufacturers hold a share about 30%.

The largest market is North America, has a share over 30%, followed by Europe and Asia Pacific, with around 32% and 20% market share respectively.

In terms of product, Exome Sequencing is the largest segment, with a share about 45%. And in terms of application, the largest application is Hospitals, has a share over 45%, followed by Specialty Clinics, Research Institutes and Diagnostics Laboratories.

With the growing clinical burden of diseases such as Alzheimer’s, Parkinson’s, epilepsy, and autism spectrum disorders, genetic testing is becoming a critical tool for early diagnosis, risk prediction, and personalized treatment. Advances in next-generation sequencing (NGS), whole-exome sequencing (WES), and whole-genome sequencing (WGS) have significantly reduced costs while improving accuracy and efficiency, accelerating adoption in clinical practice. At the same time, pharmaceutical companies and healthcare providers are increasingly integrating neurogenetic testing into drug development and clinical trials to identify potential therapeutic targets and companion diagnostics.

This report presents a comprehensive overview of the global Neurogenetic Testing market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Exome Sequencing
• Whole Genome Sequencing
• RNA Sequencing
• General DNA Testing

Segment by players, this report covers

• Quest Diagnostics
• Mayo Clinic
• GeneDx
• Illumina
• Labcorp (Invitae/MNG Laboratories)
• MedGenome Labs
• Connecticut Children's
• CENTOGENE
• Victorian Clinical Genetics Services
• PacBio

Segment by Application

• Hospitals
• Specialty Clinics
• Research Institutes
• Diagnostics Laboratories

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Neurogenetic Testing market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospitals, Specialty Clinics, Research Institutes evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact